ClinicalTrials.gg
CompletedNCT05942365Updated Dec 6, 2023

A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

A Phase 1 interventional study of ZSP1273 in Drug Drug Interaction, Warfarin and Midazolam, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a single-center, open label phase I clinical study to characterize the DDIs potential of ZSP1273 With Warfarin and Midazolam in Chinese healthy participants. This study also aims to evaluate the safety and tolerability of ZSP1273 in the presence of Warfarin and Midazolam.

02

Conditions studied

  • Drug Drug Interaction
  • Warfarin
  • Midazolam
03

In context

Lead sponsor

Guangdong Raynovent Biotech Co., Ltd is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult, male and female participants, 18 to 55 years of age, inclusive, at first Check-In Visit;
  2. (BMI) ≥19 to ≤26kg/m2 and total body weight >50 kg(male) or >45kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared);
  3. Ability to understand and willingness to sign a written form;
  4. Normal physical examination, vital signs, 12-lead , Chest X-ray images (anteroposterior) and clinical laboratory values, or any abnormality that is non-.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history of to study drug(ZSP1273,warfarin, midazolam) or any component of study medication;
  2. Participants with a history of and/or signs and symptoms of current abnormal hemostasis or blood dyscrasia or abnormal (PT), international normalized ratio (INR), or activated partial thromboplastin time at screening;
  3. Smoking more than 5 cigarettes per day within 3 months prior to screening,or who cannot stop using any tobacco products during the study period;
  4. Participants who donated blood/bleeding profusely (> 400 mL) 3 months prior to randomization;
  5. Those with abnormalities, or > 450ms in men and QTcF > 470ms in women;
  6. Participants who test positive at screening for (HIV), surface antigen (HBsAg), virus (HCV) antibody or Syphilis spirochete-specific antibodies (TPPA);
  7. Participants who test positive at Screening and/or admission (Day -1) for alcohol abuse.
  8. Females who are pregnant, lactating, or likely to become pregnant during the study.
  9. History of dysphagia or any gastrointestinal disorder that affect absorption
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    The DDI of ZSP1273 ,Warfarin and Midazolam

    Warfarin and midazolam will be co-administered alone and in combination with ZSP1273.

    Drug: ZSP1273

Interventions

  • Drug Warfarin oral Drug midazolam oral

06

What researchers measure

Primary outcomes

  1. S-warfarin Maximum Plasma Concentration [Cmax]

    To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of S-warfarin

    Time frame: Day1 to Day28

  2. Midazolam Maximum Plasma Concentration [Cmax]

    To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of midazolam and its active metabolite alpha-hydroxymidazolam

    Time frame: Day1 to Day28

  3. S-warfarin Area under the curve[AUC0-inf]

    To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of S-warfarin

    Time frame: Day1 to Day28

  4. Midazolam Area under the curve[AUC0-inf]

    To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of midazolam and its active metabolite alpha-hydroxymidazolam

    Time frame: Day1 to Day28

Secondary outcomes

  1. Number of participants with adverse events and serious adverse events

    To assess the safety and tolerability of ZSP1273 following single and multiple-dose administration with and without midazolamin+S-warfarin in healthy participates

    Time frame: Day1 to Day28

07

Study locations

1 site
  • the Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 12, 2023
StartActual
Jun 25, 2023
Primary completionActual
Jul 21, 2023
CompletionActual
Aug 4, 2023
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05942365
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Jun 25, 2023
Primary completion
Jul 21, 2023
Completion
Aug 4, 2023
Last update
Dec 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1273

Start the discussion